eif-3.E Antibody

What is eIF-3.E and what is its function within the eIF3 complex?

eIF-3.E (also known as eIF3E or INT6) is one of 13 non-identical subunits that comprise the eukaryotic translation initiation factor 3 (eIF3) complex. This multiprotein complex ranges in size from 25 to 170 kDa with an apparent total molecular weight of approximately 650 kDa . eIF-3.E functions as a component of this complex, which plays a crucial role in several steps of protein synthesis initiation .

The eIF3 complex facilitates ribosomal scanning and promotes the joining of the 60S ribosomal subunit to the translation initiation complex, thereby enabling efficient protein synthesis . It primarily ensures assembly of the 43S pre-initiation complex by direct recruitment of the 40S ribosomal subunit . Recent evidence suggests eIF3 also plays non-canonical roles in translation activation/repression through direct mRNA interactions, particularly at 5'- and 3'-UTRs .

How does eIF-3.E antibody detection help understand translation initiation mechanisms?

eIF-3.E antibodies serve as valuable tools for investigating the complex mechanisms of translation initiation by:

• Enabling detection and quantification of eIF-3.E in various cellular contexts

• Facilitating the study of eIF-3.E subcellular localization through immunofluorescence techniques

• Supporting co-immunoprecipitation experiments to identify protein interaction partners

• Allowing researchers to monitor eIF-3.E expression changes during cellular processes

These applications help researchers understand how eIF-3.E contributes to the formation of the translation pre-initiation complex, its interactions with other initiation factors like eIF1, eIF2, and eIF5 , and its potential role in mRNA circularization that promotes efficient recycling of ribosomes and translation factors for successive rounds of translation .

What are the optimal techniques for detecting eIF-3.E in different experimental contexts?

The optimal detection technique depends on your specific research question:

Since eIF3 is mainly located in the cytoplasm, immunofluorescence typically reveals a fine cytoplasmic speckled pattern . When designing experiments, it's critical to consider that eIF-3.E functions as part of a larger complex, and its detection might be affected by complex formation or dissociation.

How should researchers validate the specificity of eIF-3.E antibodies?

Validating antibody specificity is crucial for reliable experimental results. Consider these approaches:

• Multiple antibody validation: Compare results using antibodies targeting different epitopes of eIF-3.E

• Knockdown/knockout controls: Include samples where eIF-3.E expression is reduced via siRNA or CRISPR

• Recombinant protein competition: Pre-incubate antibody with purified eIF-3.E protein to block specific binding

• Mass spectrometry confirmation: Verify identity of immunoprecipitated proteins through MALDI-TOF analysis, similar to the approach used in identifying eIF3 autoantigen

• Western blot molecular weight verification: Confirm detection at the expected molecular weight (~48 kDa)

For immunoprecipitation experiments, confirm successful pull-down using western blotting techniques, as demonstrated in studies of eIF3 complex where IPP-Western blotting with commercial antibodies provided verification .

How can eIF-3.E antibodies be used to study the role of eIF3 in mRNA 3'-UTR binding?

Recent research has revealed that eIF3 engages with 3'-UTR termini of highly translated mRNAs, suggesting a novel regulatory mechanism . To investigate this phenomenon using eIF-3.E antibodies:

• Crosslinking and Immunoprecipitation (CLIP): Implement Quick-irCLIP using eIF-3.E antibodies to identify RNA transcripts that interact with eIF-3.E. This approach revealed that eIF3 primarily interacts with 3'-UTRs and to a lesser extent with CDS regions and 5'-UTRs .

• Alternative Polyadenylation (APA) Analysis: Combine eIF-3.E immunoprecipitation with sequencing to investigate how eIF-3.E engagement at 3'-UTR ends depends on polyadenylation .

• Ribosome Profiling Integration: Correlate eIF-3.E binding patterns with translational activity by performing ribosome profiling experiments in parallel with eIF-3.E immunoprecipitation .

• Proximity Ligation Assays: Use eIF-3.E antibodies in conjunction with antibodies against poly(A) binding proteins to visualize and quantify interactions between translation machinery and mRNA 3' ends.

This research approach can help elucidate eIF-3.E's potential role in mRNA circularization, supporting efficient recycling of ribosomes and translation factors .

What strategies are recommended for studying eIF-3.E in multiprotein complexes?

eIF-3.E functions within larger protein complexes, including interactions with other eIFs. Consider these approaches:

• Sequential Immunoprecipitation: First immunoprecipitate with eIF-3.E antibody, then with antibodies against other complex components to isolate specific subcomplexes.

• Gradient Centrifugation Analysis: Use sucrose gradient centrifugation followed by eIF-3.E immunoprecipitation to separate different complex forms, similar to the approach that identified eIF2/eIF3/eIF5 complexes .

• Size Exclusion Chromatography: Combine with western blotting using eIF-3.E antibodies to identify complex components, as demonstrated in studies showing eIF3/eIF5 binary complexes as the major form of eIF3 in cell extracts .

• Mass Spectrometry of Cross-linked Complexes: Cross-link protein complexes before immunoprecipitation with eIF-3.E antibodies to capture transient interactions, then identify components via mass spectrometry.

These methods help decipher how eIF-3.E participates in various complexes including eIF2/eIF3/eIF5 and eIF3/eIF5 binary complexes, providing insight into translation initiation mechanisms .

How can eIF-3.E antibodies be applied to study neuronal development and translation regulation?

eIF3 plays significant roles in neural development, particularly during differentiation of human pluripotent stem cell (hPSC)-derived neural progenitor cells (NPCs) . Researchers can:

• Temporal Expression Analysis: Use eIF-3.E antibodies for western blotting to track expression changes during neuronal differentiation stages.

• Cell-Type Specific Localization: Employ immunofluorescence with eIF-3.E antibodies alongside neuronal markers to characterize expression patterns in different neural cell populations.

• Translational Burst Investigation: Study eIF-3.E's role in the global increase in protein synthesis during stem cell differentiation by combining polysome profiling with eIF-3.E detection .

• Transcriptome-Wide Binding Analysis: Apply CLIP techniques with eIF-3.E antibodies to identify neurologically-relevant transcripts bound by eIF3, which have shown enrichment in processes like "generation of neurons," "neuron differentiation," and "axon development" .

The eIF3 complex has been shown to crosslink with different sets of transcripts across cell types, with minimal overlap between neural progenitors and other cell lines like Jurkat T cells or HEK293T , highlighting the importance of cell-type specific analysis.

What is the significance of eIF-3.E antibodies in studying autoimmune conditions?

Autoantibodies against the eIF3 complex have been identified in certain autoimmune conditions, particularly in patients with polymyositis (PM) . Researchers investigating this connection should:

• Patient Sample Analysis: Use commercial eIF-3.E antibodies as controls when screening patient samples for autoantibodies, comparing immunoprecipitation patterns.

• Epitope Mapping: Determine which eIF3 subunits, potentially including eIF-3.E, are targeted by autoantibodies through immunoprecipitation-western blot experiments with specific antibodies .

• Functional Impact Assessment: Investigate whether autoantibodies against eIF-3.E affect translation initiation by comparing in vitro translation efficiency in the presence of purified patient IgG versus control IgG.

• Clinical Correlation Studies: Correlate the presence of eIF-3.E autoantibodies with clinical features and treatment responses, as anti-eIF3 autoantibodies appear to associate with favorable prognosis and good response to immunosuppression .

Research has shown that anti-eIF3 autoantibodies were found in 0.44% of PM patients, with these patients showing absence of malignancy and interstitial lung disease . This suggests eIF-3.E antibodies could be valuable biomarkers in stratifying autoimmune disease subtypes.

What are common challenges in eIF-3.E antibody experiments and how can they be addressed?

When working with eIF-3.E antibodies, researchers often encounter several challenges:

A significant consideration is that eIF3 subunits can exist in different complexes. For example, gel filtration studies showed that eIF2/eIF3/eIF5 complexes can dissociate into free eIF3 and eIF2/eIF5 complexes , which may affect experimental outcomes.

How should researchers interpret conflicting data about eIF-3.E subcellular localization?

When facing conflicting data about eIF-3.E localization:

• Consider Cell Type Differences: The binding patterns of eIF3 vary dramatically across different cell types and physiological conditions . Compare your results with published data for similar cell types.

• Analyze Physiological State: Evaluate whether cellular stress, differentiation state, or cell cycle phase might affect localization, as eIF3 modulates translation of mRNAs critical for adaptation under stress conditions .

• Assess Technical Factors: Different fixation methods, antibody clones, or detection techniques may yield varying results. Use multiple technical approaches to confirm findings.

• Examine Complex Formation: eIF-3.E may show different localization patterns depending on its incorporation into various complexes. Co-staining with markers for different eIF3 subcomplexes can help clarify this.

Remember that eIF3 is mainly located in the cytoplasm with a fine cytoplasmic speckled pattern , but its distribution may change under specific conditions or in different cell types.